Aptamers for Treatment and Diagnosis of Autoantibody-based dilated Cardiomyopathy
Cardiovascular diseases still are a major cause of death despite the enormous efforts in cardiac therapy. Several factors may influence the onset and progression of the disease, and consequently, many forms of cardiovascular diseases can be observed. In approximately 70% of idiopathic dilated cardiomyopathy (DCM) patients and in nearly 100% of patients with Chagas’ cardiomyopathy and peripartum cardiomyopathy, antibodies to the beta1- adrenergic receptor are detected. With a prevalence of 36 cases per 100,000 people for idiopathic DCM, and a prevalence of 1,000 cases per 100,000 people (Latin America) for Chagas’ cardiomyopathy, reliable means for auto-antibody diagnostics and cause-specific therapies are required.
The technology relates to novel high-affinity aptamers specifically binding to auto-antibodies directed against the second extracellular loop of human beta1-adrenergic receptors. Due to the strong and specific binding, the aptamers can be used in a bioassay for antibody detection, enabling therapeutic decisions for depletion of pathogenic auto-antibodies by unspecific or specific immune aphaeresis. Furthermore, the aptamers have therapeutic potential for treatment of idiopatic DCM, Chagas’ cardiomyopathy and peripartum cardiomyopathy through selective inhibition of beta1-adrenergic auto-antibodies.
In-licensing and/or collaboration opportunity for development of a diagnostic tool or a novel therapeutic approach.
A European patent application hold by Charité – Universitätsmedizin Berlin, Max-Delbrück-Centrum für Molekulare Medizin, and Aptares AG is pending (unpublished).